Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations
Author:
Funder
Capital Foundation of Medical Developments
CAMS innovation Fund for Medical Sciences
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Link
http://link.springer.com/article/10.1007/s00277-017-3094-7/fulltext.html
Reference19 articles.
1. Kim Y, Ju H, Kim DH et al (2014) CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Hum Pathol 45:556–564
2. Davis RE, Ngo VN, Lenz G et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88–92
3. Gonzalez-Aguilar A, Idbaih A, Boisselier B et al (2012) Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 18:5203–5211
4. Montesinos-Rongen M, Godlewska E, Brunn A et al (2011) Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 122:791–792
5. Kraan W, Horlings HM, van Keimpema M et al (2013) High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immuneprivileged sites. Blood Cancer J 3:e139
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Benefit of consolidative radiation in patients with extranodal limited-stage diffuse large B-cell lymphoma: a multicenter retrospective study in China;Annals of Hematology;2024-06-26
2. Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome;Cancers;2024-06-07
3. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features;Blood Advances;2024-04-12
4. Predicting central nervous system relapse in primary breast diffuse large B-cell lymphoma using the stage-modified IPI score: A retrospective cohort study;Heliyon;2024-03
5. Primary breast diffuse large B‐cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group;Cancer Medicine;2023-11-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3